HURA
HURA clinical trials: TuHURA Biosciences, Inc./NV
Every trial on ClinicalTrials.gov where TuHURA Biosciences, Inc./NV is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 7
- Trials linked
- 7
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
HURA on the catalyst calendar · HURA registry changes
- Primary completion Dec 2028Sponsor estimatePhase 1/Phase 2NCT07939971A Study of TBS-2025 Monotherapy in Participants With r/r NPM1mut AMLTuHURA Biosciences, Inc. · Acute Myeloid LeukemiaNot yet recruitingHURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2027Sponsor estimatePhase 1NCT06940440IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)TuHURA Biosciences, Inc. · Advanced Or Metastatic Merkel Cell CarcinomaRecruitingHURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2027Sponsor estimatePhase 2/Phase 3NCT06947928Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic...TuHURA Biosciences, Inc. · Advanced Or Metastatic Merkel Cell CarcinomaRecruitingHURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 19, 2023ActualPhase 1NCT04160065Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin CancersTuHURA Biosciences, Inc. · Merkel Cell CarcinomaCompletedHURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT04853602IFx-Hu2.0 Expanded Access ProgramTuHURA Biosciences, Inc. · Cutaneous Melanoma, Stage IIIAvailableHURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 7, 2021ActualPhase 1NCT04925713IFx-Hu2.0 for the Treatment of Patients With Skin CancerTuHURA Biosciences, Inc. · Cutaneous Squamous Cell CarcinomaCompletedHURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 10, 2020ActualEarly Phase 1NCT03655756pDNA Intralesional Cancer Vaccine for Cutaneous MelanomaTuHURA Biosciences, Inc. · Cutaneous Melanoma, Stage IIICompletedHURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner